ArticleMolecules (Basel, Switzerland)2024
Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model.
Rawiwan Wongnak, Subbaian Brindha, Mami Oba, Takahiro Yoshizue, Md Din Islam, M Monirul Islam, Hitoshi Takemae, Tetsuya Mizutani, Yutaka Kuroda
Abstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Rawiwan WongnakDepartment of Biotechnology and Life Science, Faculty of Engineering, Tokyo University of Agriculture and Technology, Nakamachi 2-24-16, Tokyo 184-8588, Japan.
Subbaian BrindhaDepartment of Biotechnology and Life Science, Faculty of Engineering, Tokyo University of Agriculture and Technology, Nakamachi 2-24-16, Tokyo 184-8588, Japan.
Mami ObaInstitute of Global Innovation Research, Tokyo University of Agriculture and Technology, Tokyo 183-8538, Japan.ORCID 0000-0002-4187-3217 Takahiro YoshizueDepartment of Biotechnology and Life Science, Faculty of Engineering, Tokyo University of Agriculture and Technology, Nakamachi 2-24-16, Tokyo 184-8588, Japan.
Md Din IslamDepartment of Biotechnology and Life Science, Faculty of Engineering, Tokyo University of Agriculture and Technology, Nakamachi 2-24-16, Tokyo 184-8588, Japan.ORCID 0000-0003-3021-3114 M Monirul IslamDepartment of Biochemistry and Molecular Biology, Faculty of Biological Sciences, University of Chittagong, Chittagong 4331, Bangladesh.
Hitoshi TakemaeInstitute of Global Innovation Research, Tokyo University of Agriculture and Technology, Tokyo 183-8538, Japan.ORCID 0000-0003-3003-970X Tetsuya MizutaniInstitute of Global Innovation Research, Tokyo University of Agriculture and Technology, Tokyo 183-8538, Japan.
Yutaka KurodaDepartment of Biotechnology and Life Science, Faculty of Engineering, Tokyo University of Agriculture and Technology, Nakamachi 2-24-16, Tokyo 184-8588, Japan.ORCID 0000-0002-3221-4295 Funding
Institute for Fostering Leadership to create future value through Outstanding Research, Innova-tion and Sustainable Higher education (FLOuRISH) R.W.Japan Science and Technology Agency Open Innovation Platform with enterprisesJapan Society for the Promotion of Science KAKENHI-18H02385
6 · The paper itselfAbstract
The Omicron BA.5 variant of SARS-CoV-2 is known for its high transmissibility and its capacity to evade immunity provided by vaccine protection against the (original) Wuhan strain. In our prior research, we successfully produced the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein in an
Indexed as
Angiotensin-Converting Enzyme 2Antibodies, NeutralizingCOVID-19COVID-19 VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsAntibodies, ViralDisease Models, AnimalEscherichia coliFemaleGlycosylationHumansMiceProtein BindingProtein DomainsACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2disulfide bondsE. coli-expression systemimmunogenicitylimited proteolysismolten globule statenative-like stateneutralizationnon-glycosylationOmicron SARS-CoV-2
Identifiers
PMID38893549
PMCPMC11173568
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390